Litcius/Paper detail

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer

Alexis Vrachimis, Ιoannis Iakovou, Evanthia Giannoula, Luca Giovanella

2020European Journal of Endocrinology49 citationsDOIOpen Access PDF

Abstract

Most patients with thyroid nodules and thyroid cancer (TC) referred for diagnostic work-up and treatment are not considered at higher risk of infection from SARS-CoV-2 compared to the general population. On the other hand, healthcare resources should be spared to the maximum extent possible during a pandemic. Indeed, while thyroid nodules are very common, only a small percentage are cancerous and, in turn, most thyroid cancers are indolent in nature. Accordingly, diagnostic work-up of thyroid nodules, thyroid surgery for either benign or malignant thyroid nodules and radioiodine treatment for differentiated thyroid cancers may be safely postponed during SARS-CoV-2 pandemic. Appropriate patient counselling, however, is mandatory and red flags should be carefully identified prompting immediate evaluation and treatment as appropriate. For these selected cases diagnostic work-up (e.g. ultrasound, scintigraphy, fine-needle aspiration), surgery and radioiodine therapy may proceed despite the threat of SARS-CoV-2 infection and COVID-19, after an individual risk-benefit analysis.

Topics & Concepts

Internal medicineCoronavirus disease 2019 (COVID-19)EndocrinologyThyroid nodulesThyroid cancer2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineThyroidPathologyDiseaseInfectious disease (medical specialty)OutbreakThyroid Cancer Diagnosis and TreatmentCOVID-19 and healthcare impactsRadiation Dose and Imaging
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer | Litcius